Massachusetts Financial Services Co. MA increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,486,694 shares of the medical instruments supplier's stock after buying an additional 336,110 shares during the quarter. Massachusetts Financial Services Co. MA owned 3.33% of Becton, Dickinson and Company worth $1,841,083,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in the business. Crux Wealth Advisors raised its stake in Becton, Dickinson and Company by 0.8% during the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier's stock worth $1,222,000 after buying an additional 49 shares during the period. McElhenny Sheffield Capital Management LLC raised its stake in Becton, Dickinson and Company by 3.6% during the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier's stock worth $309,000 after buying an additional 55 shares during the period. Focus Financial Network Inc. raised its stake in Becton, Dickinson and Company by 2.2% during the 3rd quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier's stock worth $504,000 after buying an additional 58 shares during the period. Phillips Wealth Planners LLC raised its stake in Becton, Dickinson and Company by 2.7% during the 3rd quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier's stock worth $430,000 after buying an additional 58 shares during the period. Finally, Union Bancaire Privee UBP SA increased its holdings in Becton, Dickinson and Company by 25.7% during the 4th quarter. Union Bancaire Privee UBP SA now owns 289 shares of the medical instruments supplier's stock worth $56,000 after purchasing an additional 59 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.
Analyst Ratings Changes
A number of equities analysts have issued reports on the company. TD Cowen increased their target price on Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a "hold" rating in a report on Wednesday, February 11th. The Goldman Sachs Group assumed coverage on Becton, Dickinson and Company in a report on Friday. They set a "neutral" rating and a $167.00 target price for the company. Wells Fargo & Company lowered their target price on Becton, Dickinson and Company from $184.00 to $157.00 and set an "equal weight" rating for the company in a report on Tuesday, February 10th. Jefferies Financial Group lowered their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a "buy" rating for the company in a report on Tuesday, February 10th. Finally, Argus lowered their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating for the company in a report on Monday, March 23rd. Six research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $189.69.
Check Out Our Latest Analysis on Becton, Dickinson and Company
Becton, Dickinson and Company Price Performance
BDX stock opened at $154.07 on Friday. The stock has a market cap of $43.87 billion, a PE ratio of 25.13, a price-to-earnings-growth ratio of 11.06 and a beta of 0.29. The stock has a 50-day moving average price of $170.95 and a two-hundred day moving average price of $185.37. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.81 by $0.10. The company had revenue of $4.49 billion during the quarter, compared to analysts' expectations of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.Becton, Dickinson and Company's revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter last year, the company earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th were issued a $1.05 dividend. The ex-dividend date was Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 68.52%.
Becton, Dickinson and Company declared that its Board of Directors has authorized a stock buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.
Insider Activity
In other news, EVP Michael David Garrison sold 1,610 shares of the firm's stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bertram L. Scott sold 953 shares of the firm's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director owned 36,763 shares of the company's stock, valued at $6,713,291.43. The trade was a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,713 shares of company stock valued at $536,881 in the last 90 days. 0.40% of the stock is owned by corporate insiders.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A forward-looking investment report spotlighting the seven space companies best positioned to benefit from accelerating commercialization in 2026. It explores key industry trends, major growth catalysts, and the stocks shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.
Get This Free Report
